CAMBRIDGE, Mass. June 15, 2025 (GLOBE NEWSWIRE) - Intellia Therapeutics, Inc. (NASDAQ:NTLA), a clinical-stage gene editing company, has announced three-year follow-up data from the Phase 1 portion of its ongoing Phase 1/2 study in patients with hereditary angioedema $(HAE)$ using a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). The results were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, United Kingdom. The Phase 3 HAELO trial, a global, randomized, double-blind, placebo-controlled study, has completed screening ahead of schedule, with over half of the participants screened in the United States. Intellia plans to report the outcomes of the Phase 3 study in the first half of 2026 and aims to submit a biologics license application $(BLA.AU)$ in 2026 to support a U.S. launch in 2027.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.